Product image of Macrogol Aurovitas (Macrogol 4000) supplied by GNH India

Macrogol Aurovitas

Active Ingredient:
Macrogol 4000
Origin:
EU

Macrogol Aurovitas (Macrogol 4000)

Macrogol 4000, the active ingredient in Macrogol Aurovitas, is an osmotic laxative presented as an oral powder for solution for oral use. It is employed to relieve constipation and to prepare the bowel for diagnostic procedures such as colonoscopy.

GNH India supplies Macrogol Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards, is manufactured under GMP conditions, and its consistent purity and performance support clinical use across diverse patient populations.

Manufacturer / TM Owner

Aurovitas Spain,s.A.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Macrogol Aurovitas (macrogol 4000) is an osmotic laxative used to manage conditions involving reduced bowel motility.

  • Constipation: softens stool and facilitates regular bowel movements.
  • Chronic idiopathic constipation: provides long‑term relief of infrequent stools.
  • Bowel preparation for colonoscopy: clears intestinal contents before diagnostic procedures.
  • Fecal impaction: helps evacuate impacted stool in acute settings.

How It Works

  • Macrogol 4000 is a high‑molecular‑weight polyethylene glycol that is minimally absorbed from the gastrointestinal tract. It exerts an osmotic effect by retaining water within the intestinal lumen, increasing stool water content, softening the fecal mass, and stimulating peristaltic activity, thereby promoting bowel evacuation without significant systemic exposure.

Side Effects

Macrogol Aurovitas may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Abdominal bloating: sensation of fullness or swelling in the abdomen.
  • Flatulence: increased intestinal gas.
  • Nausea: mild feeling of queasiness.
  • Abdominal discomfort: cramping or mild pain.
  • Diarrhea: loose stools occurring more frequently.
  • Increased thirst: sensation of needing more fluids.

Serious or Rare Side Effects

  • Severe electrolyte imbalance: abnormal levels of sodium, potassium, or other electrolytes.
  • Allergic reaction: rash, itching, or angioedema.
  • Dehydration: excessive loss of body fluids.
  • Severe abdominal pain: intense or persistent pain.
  • Rectal bleeding: presence of blood in stool.
  • Anaphylaxis: rare life‑threatening allergic response.

Precautions & Warnings

When prescribing or dispensing Macrogol Aurovitas, consider the following safety measures.

  • Assess renal function: avoid use in patients with severe renal impairment.
  • Monitor electrolytes: especially during prolonged therapy.
  • Use with caution in the elderly: higher risk of dehydration.
  • Avoid in intestinal obstruction: may exacerbate blockage.
  • Review concomitant medications: potential for reduced absorption of other oral drugs.
  • Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Avoid Interactions

Macrogol 4000 can interact with other agents that affect gastrointestinal function or fluid balance.

Major Interactions (Avoid)

  • Other osmotic laxatives (e.g., lactulose): risk of severe diarrhea.
  • Mineral oil: may reduce laxative efficacy.
  • Diuretics: increased risk of electrolyte disturbances.

Moderate Interactions (Monitor Closely)

  • Antacids: may alter absorption of certain oral medications.
  • Oral antibiotics: potential changes in gut flora; monitor therapeutic response.
  • NSAIDs: increased likelihood of gastrointestinal irritation.
  • Oral supplements (e.g., iron): may have reduced absorption due to altered transit time.

Frequently Asked Questions

Macrogol Aurovitas contains macrogol 4000, an osmotic laxative that is used to relieve constipation, manage chronic idiopathic constipation, and to prepare the bowel for procedures such as colonoscopy by clearing intestinal contents.

Macrogol 4000 is a high‑molecular‑weight polyethylene glycol that remains largely unabsorbed in the gut. It draws water into the intestinal lumen by osmotic pressure, increasing stool water content, softening the stool, and stimulating peristalsis to promote bowel movements.

The dose of Macrogol Aurovitas is determined by the prescribing healthcare professional based on the patient’s condition, age, and response to therapy. The prescriber will provide specific instructions on the amount to dissolve and the frequency of administration.

Safety data for macrogol 4000 in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks and consider alternative treatments if appropriate. Women who are pregnant or breastfeeding should discuss use with their physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with stimulant laxatives, macrogol 4000 works by osmotic water retention rather than stimulating intestinal nerves, resulting in a gentler, more physiologic bowel movement. It is often preferred for long‑term use because it has a lower risk of electrolyte imbalance and habit‑forming effects.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Macrogol Aurovitas is supplied as an oral powder that is dissolved in water or another clear fluid according to the prescriber’s instructions. The solution is then ingested, typically once daily, unless otherwise directed by a healthcare professional.

Serious risks, though rare, include severe electrolyte disturbances, dehydration, allergic reactions such as rash or anaphylaxis, and significant abdominal pain or rectal bleeding. Patients should seek immediate medical attention if any of these symptoms occur.

Macrogol Aurovitas should be avoided in patients with known hypersensitivity to macrogol or polyethylene glycol, in those with intestinal obstruction, severe renal impairment, or in individuals for whom an osmotic laxative is contraindicated. Clinical judgment is required for each case.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Macrogol 4000

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT